Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03310541 · ClinicalTrials.gov registry record · Phase 1
AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT03310541: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03310541 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03310541, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study will test the recommended dose of AZD5363 (recommended from a previous phase 1 study of the drug) in patients with specific AKT mutations. In patients who have ER positive breast cancer with an AKT mutation, they will also be receiving a standard breast cancer drug called fulvestrant that is given as an injection. In patients who have prostate cancer with an AKT mutation, they will also be receiving a standard prostate cancer drug called enzalutamide that is taken orally.
Interventions
- DRUG Fulvestrant
- DRUG Enzalutamide
- DRUG AZD5363
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-10-11 |
| Est. Completion | 2023-05-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03310541
The ClinicalTrials.gov registry entry for NCT03310541 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Fulvestrant is the first listed.
NCT03310541 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03310541 about?
NCT03310541 is a clinical study titled "AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations". This study will test the recommended dose of AZD5363 (recommended from a previous phase 1 study of the drug) in patients with specific AKT mutations. In patients who have ER positive breast cancer with an AKT mutation, they will also be receiving a standard breast cancer drug called fulvestrant that...
What is the current status of trial NCT03310541?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2017-10-11. Estimated completion is 2023-05-03.
What interventions are being tested in trial NCT03310541?
The interventions under investigation include: Fulvestrant (DRUG), Enzalutamide (DRUG), AZD5363 (DRUG).
Who is sponsoring clinical trial NCT03310541?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.